“Abivax” and the Abivax logo and other trademarks or service marks of Abivax SA in this press release are the property of Abivax SA. All other trademarks, trade names and service marks ...

JMP Securities initiated coverage of Abivax (ABVX) with an Outperform rating and $33 price target Abivax is focused on the development and commercialization of obefazimod, a novel immune modulator for ...

“Abivax” and the Abivax logo and other trademarks or service marks of Abivax SA in this press release are the property of Abivax SA. All other trademarks, trade names and service ...

PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing ...

JMP Securities analyst Jason Butler initiated coverage with a Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report) yesterday and set ...

PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical ...

PARIS - Abivax SA (EPA:ABVX) (Euronext (EPA:ENX) Paris and Nasdaq: ABVX), a biotech firm specializing in immune regulation therapies for inflammatory diseases, announced today the appointment of ...